Pulmonary Arterial Hypertension Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Pulmonary Arterial Hypertension Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Pulmonary Arterial Hypertension Market is projected to register a CAGR of 5.0% during the forecast period (2022-2027).

Coronavirus disease 2019 (COVID-19) is a primary respiratory infectious disease, which can result in pulmonary and cardiovascular complications. As per an article titled “Pulmonary Hypertension and COVID-19” published in August 2022, echocardiographic signs of PH in approximately 12 to 13% of hospitalized patients with COVID-19. Those with chronic pulmonary obstructive disease, congestive heart failure, pulmonary embolism, and prior PH are at increased risk to develop or worsen pulmonary hypertension (PH). Evidence of PH seems to be associated with increased disease severity and poor outcome. Because of the importance of pulmonary hemodynamics in the pathophysiology of COVID-19, there is growing interest in exploring the potential therapeutical benefits of inhaled vasodilators in patients with COVID-19. As per an article titled “Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective” published in December 2021, the dynamic behavior of the SARS-CoV-2 virus and the potential causes of heterogeneity in COVID-19 are essential for anticipating and treating the disease, in both the acute and the chronic stages, including the development of chronic pulmonary hypertension. Both COVID-19 and chronic pulmonary hypertension have assumed global dimensions, with potentially complex interactions. Therefore, pulmonary hypertension is said to have a significant impact on the market during the pandemic.

Pulmonary arterial hypertension is a group of rare and life-threatening diseases that leads to increased pulmonary arterial pressure and localized hypertension, which can result in heart failure. As per an article titled “Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study” published in January 2022, pulmonary arterial hypertension (PAH) is characterized by increased resistance in the pulmonary arterioles because of remodeled blood vessels. The prevalence ranged from 0.4 to 1.4 per 100,000 persons. According to World Health Organization (WHO) key facts published in August 2021, an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries. One of the global targets for non-communicable diseases is to reduce the prevalence of hypertension by 33% between 2010 and 2030. The increasing prevalence of pulmonary arterial hypertension, government support for the development of orphan drugs, and the growing geriatric population are the main factors that are boosting the growth of the pulmonary arterial hypertension market.

According to the World Health Organization (WHO), between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. The symptoms of Pulmonary arterial hypertension include shortness of breath (dyspnea), especially during exercise, chest pain, and fainting. The increase in the number of geriatrics leads to consequences which in several cases include complications related to pulmonary arterial hypertension. The technological advancements are also steadily focusing upon the identification of new molecular pathways which contributes to the development of better treatments possible over the forecast period. All these factors boost the growth of the market.

However, patent expiration of drug molecule and side effects associated with the drugs is expected to impede the growth of the global market in the forecast period.

Key Market TrendsProstacyclin and Prostacyclin Analogs Segment is Expected to Observe Better Growth Over the Forecast Period

Prostacyclin and Prostacyclin Analogs segment is expected to show better growth in the forecast period, owing to the high sales of these drugs and the rising number of drug approvals. For instance, in June 2022, United Therapeutic Corporation announced the United States Food and Drug Administration approval of Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability. Tyvaso DPI delivers the proven efficacy of treprostinil through a little inhaler that fits in the patient's hand, making it one of the simplest ways for patients to administer a prostacyclin. According to the Genetic and Rare Diseases Information Center, data published in January 2021, the Orphan Drug Act, a rare disease affects fewer than 200,000 people in the United States. Different nations may have their official definitions of rare diseases. For instance, the European Union considers a disease to be rare if less than 1 in 2,000 people are affected by it. 1 in 10 Americans (about 30 million people) have a rare condition, and there are approximately 7,000 identified rare diseases.

As per an article titled “Prevalence and etiologies of pulmonary hypertension (PH) at Somalia-Turkey Training and Research Hospital in Mogadishu” published in December 2021, the prevalence of PH was found to be 18%, which is much higher than that of the average European countries. Similarly, as per another article titled “The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis” published in February 2022, the global incidence of PH in the Chronic obstructive pulmonary disease (COPD) population is very high, and there are significant regional and international variations. Patients with COPD should be screened for PH and contributing risk factors to reduce the burden on individuals and society. Pulmonary hypertension occurs at all ages, and the incidence of it increases with age. The high growth is attributed to changing lifestyles, in terms of lack of physical activity and increased consumption of alcohol and tobacco, which increases the chances of developing hypertension and high blood pressure. The increased blood pressure, in turn, gives rise to various diseases such as stroke and heart attacks. Hypertension is considered a variable health risk and is often related to high morbidity and mortality. Therefore, the above-mentioned factors are expected to drive the market growth of the segment.

North America is Estimated to Lead the Pulmonary Arterial Hypertension Market

North America leads the Pulmonary Arterial Hypertension (PAH) Market, owing to the presence of the highly developed healthcare sector, along with the rising prevalence of infectious and chronic diseases. As per an article titled “Learn About Pulmonary Arterial Hypertension” published in October 2020, PAH is a rare condition, with about 500-1000 new cases being diagnosed each year in the U.S. About 15-20% of patients with PAH have inherited the condition. As per an article titled “Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension” published in October 2021, Hospitalization is an important clinical factor associated with survival and rehospitalization in patients with pulmonary arterial hypertension (PAH). This is expected to drive the market in the region.

Moreover, increased awareness, high diagnosis rate, and supportive government initiatives. According to the Centers for Disease Control and Prevention, data published in August 2022, Million Hearts is a national initiative to prevent 1 million heart attacks and strokes within 5 years. It focuses on implementing a small set of evidence-based priorities and targets that can improve cardiovascular health for all. Another instance is, the World Health Organization (WHO) global HEARTS Initiative supports countries strengthening actions to prevent CVD, such as enhanced tobacco control, dietary salt reduction, increasing physical activity, elimination of industrially produced dietary trans-fat, and management of CVD risks. There are certain useful developments shown by the companies and supported by the government related to pulmonary arterial hypertension activities.

Therefore the above-mentioned factors are expected to drive the market growth in the region during the forecast period.

Competitive Landscape

The Pulmonary Arterial Hypertension Market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. The leading players in the global market for Pulmonary Arterial Hypertension are - Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co. Inc., Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.